Lv4
510 积分 2024-04-22 加入
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC
2小时前
求助中
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial
23天前
已完结
胆道恶性肿瘤诊疗专家共识（2026版）
24天前
已完结
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
1个月前
已完结
Allocating recycled significance levels in group sequential procedures for multiple endpoints
1个月前
已完结
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
1个月前
已完结
Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2-positive, locally advanced, unresectable, or metastatic pancreatic cancer
4个月前
已完结
Abstract 4260: PT886, an anti-claudin18.2/anti-CD47 bispecific antibody constructed with the PACbody࣪ and SPECpair࣪ technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model
4个月前
已关闭
Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2
5个月前
已完结
Claudin proteins as emerging therapeutic targets for solid tumours
5个月前
已完结
皖公网安备34019202002308
